Establishment of a humanized patient-derived xenograft mouse model of high-grade serous ovarian cancer for preclinical evaluation of combination immunotherapy.
Saved in:
| Title: | Establishment of a humanized patient-derived xenograft mouse model of high-grade serous ovarian cancer for preclinical evaluation of combination immunotherapy. |
|---|---|
| Authors: | Tandaric L; Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Norway.; Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway., Bjørge L; Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Norway.; Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway., Lode MR; Precision Oncology Research Group, Department of Clinical Science, University of Bergen, Norway.; Kinn Therapeutics AS, Bergen, Norway., Torkildsen CF; Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Norway.; Department of Obstetrics and Gynecology, Stavanger University Hospital, Stavanger, Norway.; Department of Obstetrics and Gynecology, Heidelberg University Hospital, Germany., Aehnlich P; Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Norway.; Precision Oncology Research Group, Department of Clinical Science, University of Bergen, Norway., Elnour R; Department of Clinical Medicine, Centre for Cancer Biomarkers CCBIO and Gade Laboratory of Pathology, University of Bergen, Norway., Costea DE; Department of Clinical Medicine, Centre for Cancer Biomarkers CCBIO and Gade Laboratory of Pathology, University of Bergen, Norway.; Department of Pathology, Laboratory Clinic, Haukeland University Hospital, Bergen, Norway., Akslen LA; Department of Clinical Medicine, Centre for Cancer Biomarkers CCBIO, Section for Pathology, University of Bergen, Norway.; Department of Pathology, Haukeland University Hospital, Bergen, Norway., Thomsen LCV; Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Norway.; Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway.; Department of Health Registry Research and Development, Norwegian Institute of Public Health, Oslo, Norway., McCormack E; Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Norway.; Centre for Pharmacy, Department of Clinical Science, University of Bergen, Norway.; Department of Internal Medicine, Hematology Section, Haukeland University Hospital, Bergen, Norway., Kleinmanns K; Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Norway.; Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway. |
| Source: | Molecular oncology [Mol Oncol] 2026 Mar 14. Date of Electronic Publication: 2026 Mar 14. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101308230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0261 (Electronic) Linking ISSN: 15747891 NLM ISO Abbreviation: Mol Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
